Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Expanded Access Program Protocol for Melphalan Flufenamide in Combination With Dexamethasone in Patients With Triple Class Refractory Multiple Myeloma

Next Previous
Search
Trial Profile

An Expanded Access Program Protocol for Melphalan Flufenamide in Combination With Dexamethasone in Patients With Triple Class Refractory Multiple Myeloma

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 19 Mar 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Melphalan flufenamide (Primary)
  • Indications Multiple myeloma
  • Focus Expanded access; Therapeutic Use
  • Acronyms sEAPort
  • Sponsors Oncopeptides

    • Most Recent Events

    • 16 Mar 2021 Status changed from discontinued to completed.
    • 01 Oct 2020 According to an Oncopeptides media release, 40 to 50 medical sites in the USA are expected to enroll 100-200 patients in this sEAPort program
    • 01 Oct 2020 According to an Oncopeptides media release, this sEAPort program is primarily supported by data from the pivotal phase 2 HORIZON study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top